

10-05-05

AP  
JFW

DOCKET NO.: ISIS-1158

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of: **Nielsen, et al.**  
Serial No.: **08/319,411**  
Filing Date: **October 6, 1994**  
For: **Peptide Nucleic Acid Conjugates**

Confirmation No.: **8648**

Group Art Unit: **1631**

Examiner: **Ardin H. Marschel**

EXPRESS MAIL LABEL NO: EV 631246708 US  
DATE OF DEPOSIT: October 4, 2005

Mail Stop Appeal-Brief Patents  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**APPELLANT'S BRIEF PURSUANT TO 37 C.F.R. § 41.37**

This brief is being filed in support of Appellants' appeal from the rejections of claims 53, 63, And 64 dated October 6, 2004. A Notice of Appeal was filed on April 5, 2005.

**1. REAL PARTY IN INTEREST**

Based on information supplied by Applicants and to the best of the undersigned's knowledge, the real parties in interest in the above-identified patent application are Peter Nielsen, who is the assignee of Soren Holst Sonnichsen and Jesper Lohse; Ole Buchardt; Michael Egholm; Rolf Henrik Berg, and ISIS Pharmaceuticals, Inc., a corporation of Delaware.

**2. RELATED APPEALS AND INTERFERENCES**

There are no other appeals or interferences known to Appellants, Appellants' legal representative, or the assignee which will directly affect or be directly affected by or have a bearing on the Board's decision in the pending Appeal. Applicants note, however, that prosecution was suspended in copending application 08/817,067 on October 1, 2002 due to a potential interference.

10/06/2005 TBESHARH1 00000047-08319411

01 Mod date: 10/06/2005 TBESHARH1 00000047-08319411  
02 10/06/2005 TBESHARH1 00000047-08319411  
02 RE-15941402  
02 FC:1254

10/06/2005 TBESHARH1 00000048 08319411  
01 FC:1402

**3. STATUS OF CLAIMS**


Claims 53, 63, and 64 are pending and are rejected for allegedly being unpatentable under the judicially created doctrine of obviousness-type double patenting over claims 1, 4, 5, and 7 of U.S. Patent No. 6,395,474 ("the 474 patent") and over claims 1 and 12 of U.S. Patent No. 6,613,873 ("the 873 patent"). The September 19, 2005 Advisory Action indicates that the rejection over claim 1 of U.S. Patent No. 5,773,571 has been overcome. The rejection of claims 53, 63, and 64 based on U.S. Patent No. 6,613,873 is appealed. Applicants have expressed a willingness to file a terminal disclaimer to remove the rejection based on U.S. Patent No. 6,395,474 once the claims otherwise are indicated as allowable.

**4. STATUS OF AMENDMENTS**

All amendments are believed to have been entered. A complete listing of currently pending claims is provided in the Claims Appendix.

**5. SUMMARY OF CLAIMED SUBJECT MATTER**

The claims are directed to peptide nucleic acids having the formula:



where m is an integer from 1 to about 50; L and  $L_m$  independently are naturally occurring nucleobases; C and  $C_m$  are  $(CR^6R^7)_y$ ;  $R^6$  and  $R^7$  are hydrogen;  $G_m$  is  $-NR^3CO-$  in either orientation;  $R^3$  is hydrogen; D and  $D_m$  are  $(CR^6R^7)_z$ ; y is 1; z is 2; each pair of A- $A_m$  and B-

$B_m$  are  $>N-C(O)-CH_2-$ ; I is  $-NR^8R^9$  or  $-NR^{10}C(O)R^{11}$  where  $R^8$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  independently are hydrogen, alkyl, an amino protecting group, a reporter ligand, an intercalator, a chelator, a peptide, a protein, a carbohydrate, a lipid, a steroid, a nucleoside, a nucleotide, a nucleotide diphosphate, a nucleotide triphosphate, an oligonucleotide, an oligonucleoside, a soluble polymer, a non-soluble polymer, a reporter enzyme, a reporter molecule, a terpene, a phospholipid, a cell receptor binding molecule, a water soluble vitamin, a lipid soluble vitamin, an RNA/DNA cleaving complex, a porphyrin, or a polymeric compound selected from polymeric amines, polymeric glycols and polyethers; and Q is  $-CO_2H$ ,  $-CO_2R^8$ , or  $-CONR^8R^9$  (see page 6, line 9 to page 10, line 20). In some embodiments,  $R^8$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  independently are hydrogen, alkyl, a peptide, a protein, a carbohydrate, a nucleoside, a nucleotide, a nucleotide diphosphate, a nucleotide triphosphate, an oligonucleotide, or an oligonucleoside (see page 10, lines 5-9). In other embodiments,  $R^8$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  independently are a nucleoside, a nucleotide, an oligonucleotide, or an oligonucleoside (*Id.*).

## 6. GROUNDS OF REJECTION TO BE REVIEWED ON APPEAL

This appeal seeks to resolve whether or not the Examiner has demonstrated, in accordance with the judicially-created doctrine of obviousness-type double patenting, that those of ordinary skill in the art would have regarded the subject matter claimed in claims 53, and 63 as an obvious variant of the subject matter claimed in claims 1 and 12 of U.S. Patent 6,613,873.

## 7. Grouping of the Claims

Claims 53 and 63 stand or fall together. Claim 64 is not subject to the appealed rejection based on claims 1 and 12 of U.S. Patent 6,613,873.

## 8. ARGUMENT

### **The Rejection Of Claims 53 and 63 Under The Judicially-Created Doctrine Of Obviousness-Type Double Patenting Based On Claims 1 and 12 Of U.S. Patent 6,613,873 Is Improper.**

The doctrine of double patenting is designed to prevent the unjustified extension of patent exclusivity beyond the term of a patent. MPEP § 804. Nonstatutory-type double

patenting rejections are based on a judicially created doctrine grounded in public policy primarily intended to prevent prolongation of the patent term by prohibiting claims in a second patent which are not patentably distinct from claims in a first patent. *Id.*; *Eli Lilly & Co. v. Barr Labs, Inc.*, 222 F.3d 973 (Fed. Cir. 2000); *In re Braat*, 937 F.2d 589, 592 (Fed. Cir. 1991); *In re Longi*, 759 F.2d 887 (Fed. Cir. 1985) (explaining that, even though no explicit statutory basis exists for obviousness-type double patenting, the doctrine is necessary to prevent a patent term extension through claims in a second patent that are not patentably distinct from those in the first patent).

Although the Examiner asserts that there is overlap among the claims (September 16, 2005 Advisory Action at page 2), no such overlap actually exists. Claims 1 and 12 of the 873 patent require that at least one L be a 2,6-diaminopurine nucleobase. In the instant claims, each L is a naturally occurring nucleobase.

As is well known, the analytic approach employed in connection with an obviousness-type double patenting determination parallels that employed in connection with a 35 U.S.C. § 103 obviousness determination. *In re Braat*, 19 U.S.P.Q.2d 1289 (Fed. Cir. 1991). Thus, even if there were overlap between the instant claims and those of the 873 patent, the MPEP cautions that this still would provide inadequate support for an obviousness rejection. On this matter, the MPEP states “[t]he fact that a claimed species or subgenus is encompassed by a prior art genus is not sufficient by itself to establish a *prima facie* case of obviousness.” MPEP § 2144.08, II. Rather, there must be a teaching that would have motivated one of ordinary skill in the art to make a claimed compound based on claims 1 and 12 of the 873 patent. *In re Fine*, 837 F.2d 1071, 1074, 5 U.S.P.Q.2D (BNA) 1596, 1598 (Fed. Cir. 1988) (obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art.).

The Examiner has failed to identify proper motivation to modify the compounds claimed in claims 1 and 12 of the 873 patent. Claims 1 and 12 of the 873 patent encompass numerous species. The amount of picking and choosing from the teachings of claims 1 and 12 of the 873 patent that would be required to arrive at any instant invention is inconsistent with obviousness. In the instant claims, L is a naturally occurring nucleobase while the 873 patent allows that L can also be non-naturally occurring nucleobases and at least one L has to be a 2,6-diaminopurine nucleobase—not a naturally occurring nucleobase. Claims 1 and 12


of the 873 patent also allow that R<sup>7</sup> is H or C<sub>1</sub>-C<sub>8</sub> alkylamine. In the instant claims, the corresponding variables R<sub>6</sub> and R<sub>7</sub> are each H. Applicants submit that these differences are significant, and that the instant claims are not obvious in view of the cited art.

The only motivation for modifying the teaching of the 873 patent that the Examiner has put forward is that genus of the cited art is so small as to make the compounds of the instant claims "immediately envisioned" (September 16, 2005 Advisory Action at page 2). This assertion is not consistent with the amount of picking and choosing needed to arrive at any claimed invention. Such picking and choosing, without any apparent motivation, is inconsistent with obviousness. Thus, Applicants submit that the rejection is improper.

## 9. CONCLUSION

For the foregoing reasons, Applicants request that this patent application be remanded to the Patent Office with an instruction to both withdraw the outstanding rejections and allow the appealed claims.

Respectfully submitted,



Date: October 4, 2005


John A. Harrelson, Jr., PhD  
Registration No. 42,637

Woodcock Washburn LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

## 10. CLAIMS APPENDIX

1-52 (canceled)

53. (previously presented) A peptide nucleic acid of the formula:



wherein:

m is an integer from 1 to about 50;

L and L<sub>m</sub> independently are naturally occurring nucleobases;C and C<sub>m</sub> are (CR<sup>6</sup>R<sup>7</sup>)<sub>y</sub>; wherein:R<sup>6</sup> and R<sup>7</sup> are hydrogen;R<sup>3</sup> is hydrogen;D and D<sub>m</sub> are (CR<sup>6</sup>R<sup>7</sup>)<sub>z</sub>;

y is 1 and z is 2;

G<sub>m</sub> is -NR<sup>3</sup>CO- in either orientation;each pair of A-A<sub>m</sub> and B-B<sub>m</sub> are >N-C(O)-CH<sub>2</sub>-;I is -NR<sup>8</sup>R<sup>9</sup> or -NR<sup>10</sup>C(O)R<sup>11</sup>; wherein:

R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> independently are hydrogen, alkyl, an amino protecting group, a reporter ligand, an intercalator, a chelator, a peptide, a protein, a carbohydrate, a lipid, a steroid, a nucleoside, a nucleotide, a nucleotide diphosphate, a nucleotide triphosphate, an oligonucleotide, an oligonucleoside, a soluble polymer, a non-soluble polymer, a reporter enzyme, a reporter molecule, a terpene, a phospholipid, a cell receptor binding molecule, a water soluble vitamin, a lipid soluble vitamin, an RNA/DNA cleaving complex, a porphyrin, or a polymeric compound selected from polymeric amines, polymeric glycols and polyethers; and

Q is -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>8</sup>, or -CONR<sup>8</sup>R<sup>9</sup>.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## In Re Application of:

Nielsen, et al

Application No.: 08/319,411

Filing Date: October 6, 1994

For: Peptide Nucleic Acid Conjugates

Confirmation No.: 8648

Group Art Unit: 1631

Examiner: Ardin H. Marschel

EXPRESS MAIL LABEL NO: EV 631246708 US  
DATE OF DEPOSIT: October 4, 2005

EV631246708US

MS Appeal Brief - Patent  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

APPEAL BRIEF TRANSMITTAL  
PURSUANT TO 37 CFR § 1.192

Transmitted herewith in triplicate is the APPEAL BRIEF in this application with respect to the Notice of Appeal received by The United States Patent and Trademark Office on **April 5, 2005**.

- Applicant(s) has previously claimed small entity status under 37 CFR § 1.27 .
- Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR § 1.27 as:
  - an Independent Inventor
  - a Small Business Concern
  - a Nonprofit Organization.
- Petition is hereby made under 37 CFR § 1.136(a) (fees: 37 CFR § 1.17(a)(1)-(4) to extend the time for response from the Notice of Appeal filed on April 5, 2005 to and through October 5, 2005 comprising an extension of the shortened statutory period of Four (04) month(s).

10/06/2005 TBESHAW1 00000048 08319411

02 FC:1254

1590.00 OP



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## In Re Application of:

Nielsen, et al

Application No.: 08/319,411

Filing Date: October 6, 1994

For: Peptide Nucleic Acid Conjugates

Confirmation No.: 8648

Group Art Unit: 1631

Examiner: Ardin H. Marschel

EXPRESS MAIL LABEL NO: EV 631246708 US  
DATE OF DEPOSIT: October 4, 2005

EV631246708US

MS Appeal Brief - Patent  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

APPEAL BRIEF TRANSMITTAL  
PURSUANT TO 37 CFR § 1.192

Transmitted herewith in triplicate is the APPEAL BRIEF in this application with respect to the Notice of Appeal received by The United States Patent and Trademark Office on **April 5, 2005**.

- Applicant(s) has previously claimed small entity status under 37 CFR § 1.27 .
- Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR § 1.27 as:
  - an Independent Inventor
  - a Small Business Concern
  - a Nonprofit Organization.
- Petition is hereby made under 37 CFR § 1.136(a) (fees: 37 CFR § 1.17(a)(1)-(4) to extend the time for response from the Notice of Appeal filed on April 5, 2005 to and through October 5, 2005 comprising an extension of the shortened statutory period of Four (04) month(s).

10/06/2005 TBESHAW1 00000048 08319411

02 FC:1254

1590.00 0P

	SMALL ENTITY		NOT SMALL ENTITY	
	RATE	Fee	RATE	Fee
<input checked="" type="checkbox"/> APPEAL BRIEF FEE	\$250	\$	\$500	\$500.00
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME	\$60	\$	\$120	\$0.00
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME	\$225	\$	\$450	\$0.00
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME	\$510	\$	\$1020	\$0.00
<input checked="" type="checkbox"/> FOUR MONTH EXTENSION OF TIME	\$795	\$	\$1590	\$1,590.00
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME	\$1080	\$	\$2160	\$0.00
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID	minus	(\$ )	minus	(\$0.00)
<b>TOTAL FEE DUE</b>		\$		<b>\$2,090.00</b>

- The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to Deposit Account 23-3050. This sheet is provided in duplicate.
- A check in the amount of \$2,090.00 is attached. Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.
- Please charge Deposit Account No. 23-3050 in the amount of \$ .00. This sheet is attached in duplicate.
- The Commissioner is hereby authorized to charge any deficiency or credit any overpayment of the fees associated with this communication to Deposit Account No. 23-3050.

Date: October 4, 2005

*John A. Harrelson, Jr.*  
 John A. Harrelson, Jr., PhD  
 Registration No. 42,637

Woodcock Washburn LLP  
 One Liberty Place - 46th Floor  
 Philadelphia PA 19103  
 Telephone: (215) 568-3100  
 Facsimile: (215) 568-3439

© 2005 WW